Organon: Humira A ‘Whole Different Animal’ To Other US Biosimilars
US-Based Firm Also In Discussions To Expand Biosimilar Pipeline
Shortly after filing for a high-concentration biosimilar adalimumab product with partner Samsung Bioepis, Organon has provided in-depth commentary for its expectations around the impending formation of the market, forecasting a “free for all” six months post-formation.
